ES2014593A6 - Un metodo para preparar un vector de acido nucleico que codifica una proteina de cr1. - Google Patents

Un metodo para preparar un vector de acido nucleico que codifica una proteina de cr1.

Info

Publication number
ES2014593A6
ES2014593A6 ES8901125A ES8901125A ES2014593A6 ES 2014593 A6 ES2014593 A6 ES 2014593A6 ES 8901125 A ES8901125 A ES 8901125A ES 8901125 A ES8901125 A ES 8901125A ES 2014593 A6 ES2014593 A6 ES 2014593A6
Authority
ES
Spain
Prior art keywords
fragments
expression
protein
secreted
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES8901125A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
T Cell Sciences Inc
Johns Hopkins University
Original Assignee
Brigham and Womens Hospital Inc
T Cell Sciences Inc
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc, T Cell Sciences Inc, Johns Hopkins University filed Critical Brigham and Womens Hospital Inc
Publication of ES2014593A6 publication Critical patent/ES2014593A6/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3153—Streptokinase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Joining Of Building Structures In Genera (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

METODO PARA PREPARAR UN VECTOR DE ACIDO NUCLEICO QUE CODIFICA UNA PROTEINA DE CR1. CONSISTE EN INTRODUCIR EN UNA CELULA UN VECTOR DE ACIDO NUCLEICO QUE COMPRENDE LA SECUENCIA DE NUCLEOTIDOS DEL GEN DEL RECEPTOR C3B/C4B (CR1), Y PROPAGAR EL VECTOR DE ACIDO NUCLEICO MEDIANTE PROPAGACION DE LA CELULA, ELIGIENDOSE ESTA PREFERIBLAMENTE ENTRE BACTERIAS Y CELULAS DE MAMIFEROS. EL INVENTO PERMITE OBTENER TAMBIEN SECUENCIAS DE ACIDOS NUCLEICOS DE CR1 Y FRAGMENTOS DE LAS MISMAS QUE CONTIENEN 70 NUCLEOTIDOS, ASI COMO SUS PEPTIDOS O PROTEINAS CODIFICADOS QUE CONTIENEN 24 AMINOACIDOS, PROPORCIONANDOSE ADEMAS LA EXPRESION DE LA PROTEINA DE CR1 Y SUS FRAGMENTOS. LOS PRODUCTOS OBTENIDOS SON UTILES EN DIAGNOSTICOS Y TERAPIA DE DIVERSAS AFECCIONES DEL SISTEMA INMUNE Y ENFERMEDADES INFLAMATORIAS.
ES8901125A 1988-04-01 1989-03-31 Un metodo para preparar un vector de acido nucleico que codifica una proteina de cr1. Expired - Lifetime ES2014593A6 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17653288A 1988-04-01 1988-04-01
US41274589A 1989-09-26 1989-09-26

Publications (1)

Publication Number Publication Date
ES2014593A6 true ES2014593A6 (es) 1990-07-16

Family

ID=26872337

Family Applications (1)

Application Number Title Priority Date Filing Date
ES8901125A Expired - Lifetime ES2014593A6 (es) 1988-04-01 1989-03-31 Un metodo para preparar un vector de acido nucleico que codifica una proteina de cr1.

Country Status (14)

Country Link
EP (1) EP0411031B1 (es)
JP (1) JP3484189B2 (es)
CN (2) CN1092712C (es)
AT (1) ATE240973T1 (es)
CA (2) CA1341443C (es)
DE (1) DE68929466T2 (es)
DK (1) DK175699B1 (es)
ES (1) ES2014593A6 (es)
FI (2) FI106316B (es)
IL (1) IL89790A (es)
NO (1) NO315944B1 (es)
SG (1) SG52789A1 (es)
WO (1) WO1989009220A1 (es)
ZA (2) ZA892397B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5426029A (en) * 1986-03-31 1995-06-20 T Cell Diagnostics, Inc. Therapeutic and diagnostic methods using leukocyte surface antigens
US5256642A (en) * 1988-04-01 1993-10-26 The Johns Hopkins University Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
SG72614A1 (en) * 1989-10-12 2000-05-23 Imutran Ltd Modified biological material
US6482404B1 (en) 1989-10-12 2002-11-19 David James White Transplantation of tissue comprising a DNA sequence encoding a homologous complement restriction factor
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US6458360B1 (en) * 1990-04-25 2002-10-01 The Johns Hopkins University Soluble complement regulatory molecules
JP4236698B2 (ja) * 1990-11-26 2009-03-11 ジェネティックス インスティチュート，リミテッド ライアビリティ カンパニー 宿主細胞でのｐａｃｅの発現およびその使用法
WO1992010205A1 (en) * 1990-12-06 1992-06-25 T Cell Sciences, Inc. Synergistic compositions of soluble complement receptors and compounds that inhibit complement and/or suppress immune activity
EP1413587A2 (en) 1991-05-03 2004-04-28 Washington University Modified complement system regulator
US5833989A (en) * 1992-06-24 1998-11-10 Adprotech Plc Soluble CR1 derivatives
US5456909A (en) * 1992-08-07 1995-10-10 T Cell Sciences, Inc. Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo
DE69431290D1 (de) * 1993-02-12 2002-10-10 Avant Immunotherapeutics Inc PULMONÄRE VERABREICHUNG DES LÖSLICHEN KOMPLEMENT-RECEPTORS TYP 1 sCR1
US5951976A (en) 1996-03-28 1999-09-14 Whitenead Institute For Biomedical Research Opsonin-enhanced cells, and methods of modulating an immune response to an antigen
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
GB9706950D0 (en) * 1997-04-05 1997-05-21 Chernajovsky Yuti Immune modulation by polypeptides related to CR1
WO2000005413A1 (en) * 1998-07-24 2000-02-03 Uab Research Foundation Genetic polymorphism in a complement receptor
US6664052B1 (en) 1998-07-24 2003-12-16 The Uab Research Foundation Genetic polymorphism in a complement receptor
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
GB9905503D0 (en) 1999-03-10 1999-05-05 Adprotech Plc Novel compound formulations and methods of delivery
EP1738763A1 (en) 2005-06-30 2007-01-03 AVANT Immunotherapeutics, Inc. Use of complement inhibitory proteins to treat spinal cord injury
LT3028716T (lt) 2006-10-10 2020-12-10 Regenesance B.V. Komplemento slopinimas nervų regeneracijos pagerinimui
US8512695B2 (en) 2008-10-21 2013-08-20 The General Hospital Corporation Method of preventing fat graft resorption by administering fat-derived cells and poloxamer P 188
WO2012019103A2 (en) 2010-08-06 2012-02-09 The General Hospital Corporation D/B/A System and apparatus for cell treatment
US9295713B2 (en) 2010-09-15 2016-03-29 Celldex Therapeutics, Inc. Treatment of chronic nephropathies using soluble complement receptor type I (sCR1)
WO2012058479A2 (en) 2010-10-27 2012-05-03 Celldex Therapeutics, Inc. Method of improving transplant function using soluble complement receptor type i (scr1)
WO2012071145A1 (en) 2010-11-02 2012-05-31 Kypha, Inc. Lateral flow immunoassay for complement activation and methods of use for point-of-care assessment of complement-associated disorders
CN102702339B (zh) * 2011-05-24 2013-10-30 华南师范大学 斜带石斑鱼补体c3基因、载体、重组菌株和蛋白及其应用
BR112014013205A2 (pt) * 2011-12-01 2020-10-27 Protevobio, Inc. proteína de fusão, seu uso e seu método de produção, composição farmacêutica, ácido nucleico, e kit
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof
CN104293836A (zh) * 2014-06-24 2015-01-21 长沙赢润生物技术有限公司 一种免疫复合物吸附细胞的制作方法
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
EP3760645A1 (en) * 2019-07-02 2021-01-06 imusyn GmbH & Co. KG Analysis for blood group antigen dacy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60192948A (ja) * 1984-03-14 1985-10-01 Fuji Photo Film Co Ltd 湿し水不要ネガ型感光性平版印刷版および製版方法
US4672044A (en) * 1984-08-24 1987-06-09 Scripps Clinic & Research Foundation Murine monoclonal antibody combining site to human C3b receptor (CR1)

Also Published As

Publication number Publication date
FI904842A0 (fi) 1990-10-01
NO315944B1 (no) 2003-11-17
DK175699B1 (da) 2005-01-24
FI20002515L (fi) 2000-11-16
DK234890A (da) 1990-11-30
CN1053924C (zh) 2000-06-28
ATE240973T1 (de) 2003-06-15
ZA907693B (en) 1992-05-27
ZA892397B (en) 1989-11-29
FI115528B (fi) 2005-05-31
CA1340866C (en) 1999-12-28
EP0411031A4 (en) 1992-02-05
JP3484189B2 (ja) 2004-01-06
EP0411031B1 (en) 2003-05-21
CA1341443C (en) 2003-10-07
WO1989009220A1 (en) 1989-10-05
DE68929466T2 (de) 2004-04-01
CN1036987A (zh) 1989-11-08
SG52789A1 (en) 1998-09-28
JPH04501502A (ja) 1992-03-19
IL89790A0 (en) 1989-09-28
DE68929466D1 (de) 2003-06-26
AU3539489A (en) 1989-10-16
NO20000827L (no) 1990-11-09
EP0411031A1 (en) 1991-02-06
CN1053265A (zh) 1991-07-24
AU647371B2 (en) 1994-03-24
NO20000827D0 (no) 2000-02-18
FI106316B (fi) 2001-01-15
CN1092712C (zh) 2002-10-16
IL89790A (en) 2002-05-23
DK234890D0 (da) 1990-09-28

Similar Documents

Publication Publication Date Title
EP0502892A4 (en) The human c3b/c4b receptor (cr1)
ES2014593A6 (es) Un metodo para preparar un vector de acido nucleico que codifica una proteina de cr1.
Gubler et al. Recombinant human interleukin 1 alpha: purification and biological characterization.
US5401651A (en) DNA encoding ENA-78, a neutrophil activating factor
Reeves et al. Molecular cloning of a functional bovine interleukin 2 cDNA.
EP0330191A3 (en) DNA encoding CD40
KR970705405A (ko) 사람 케모킨 폴리펩타이드(Human Chemokine Polypeptides)
Green et al. Identification and characterization of PF4varl, a human gene variant of platelet factor 4
NZ503235A (en) Amino-terminally truncated RANTES as chemokine antagonists
CA2062969A1 (en) Recombinantly produced human membrane cofactor protein (mcp)
Karlen et al. Biological and molecular characteristics of interleukin-5 and its receptor
MX9203654A (es) Purificacion, clonacion y caracterizacion del gen para la interleucina i.
CA2342770A1 (en) Ly6h gene
Sherry et al. Characterization of high molecular weight glycosylated forms of murine tumor necrosis factor
CA2202519A1 (en) Cloning, expression and characterization of a new form of phosphatidylinositol-3-kinase
EP0913470A3 (en) The human C3b/C4b receptor (CR1)
JP2002519016A (ja) 疎水性ドメインを有するヒト蛋白質とそれをコードするｄｎａ
KR930701475A (ko) 사람의 거핵구-집락 촉진 인자(hMeg-CSF) 및 그것의 생산방법
EP0341100A2 (en) DNA coding for thymosin and TNF
KR20010030984A (ko) 폴리펩티드, 그 폴리펩티드를 암호화하는 ｃＤＮＡ 및이들의 용도
EP0308424A1 (en) A novel protein, neuroleukin
EP0353516A2 (en) A method for the preparation of recombinant human beta interleukin-1 in the homogeneous form
WO1998004692A3 (en) Human neuronatin
JPH07309778A (ja) 創傷治療剤

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 20080401